Pharmafile Logo

payer survey

- PMLiVE

Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

- PMLiVE

MHRA approves KalVista Pharmaceuticals’ Ekterly to treat hereditary angioedema attacks

Ekterly is now the first and only oral on-demand treatment for HAE to be approved by the UK regulator

- PMLiVE

GCI Health announces realignment of European leadership team

The new structure will see Annalise Coady step into the role of president, Europe

- PMLiVE

Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering

Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position...

Uniphar

Bayer symbol

Bayer’s Kerendia granted FDA approval for new heart failure indication

Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

EU flag

EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer

The form of head and neck cancer accounted for around 133,000 new global cancer cases in 2020

- PMLiVE

Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

Around 55,100 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

NEW SENIOR ROLES AS FOUR TAKES NEXT STEP IN SECTOR & SERVICE STRATEGY

Kelly Smith and Sam Khachikyan to lead £32m turnover media service Mohaned Lafi to spearhead Middle East growth as chief executive MENA Louay Houri takes on new global role as...

Four Agency Worldwide

- PMLiVE

AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

- PMLiVE

Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

The rare inherited disease affects approximately 11,000 people in the UK

- PMLiVE

AstraZeneca’s baxdrostat shows promise in phase 3 hypertension study

Around 1.3 billion people globally are living with consistently high blood pressure levels

- PMLiVE

Innovative Trials names Hertfordshire hospice as 2025 UK charity partner

Innovative Trials, an internationally renowned clinical trials patient recruitment company based in the UK, has today announced Garden House Hospice Care as its UK charity partner for 2025/26. It continues...

Innovative Trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links